Oncology and Carcinogenesis articles for Japan

Time frame: 1 July 2025 - 30 June 2026

View topic

Count: 257

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
3 2.33
Ultrasmall Ligand-Protected Ag7 Nanoclusters Enable Dual-Mode Reactive Oxygen Species Generation under Dark and Near-Infrared Irradiation 0.40
High-Speed Atomic Force Microscopy Reveals Disordered Region-Mediated Structural Plasticity of Anaplastic Lymphoma Kinase Fusion Proteins Induced by Inhibitors 1.00
Harnessing Dye-Induced Local Heating in Lipid Membranes: A Path to Near-Infrared Light-Modulated Artificial Synaptic Vesicles 0.93
1 0.19
Allosteric DNA Nanorobots for Targeted Glioma Therapy: Acid‐Triggered Doxorubicin Delivery 0.19
4 4.00
Dual mechanisms underlie the repression of REST expression in lung neuroendocrine carcinoma cells 1.00
Molecular Switching from Morule to Squamous Metaplasia via p40 and the EBP50/S100A4/Myosin 9 Axis in Endometrial Carcinoma 1.00
Bone Marrow Stromal Cell Antigen 2 Promotes Esophageal Squamous Cell Carcinoma Progression by Mediating the Cell-Cell Interaction between Cancer Cells and Cancer-Associated Fibroblasts 1.00
Increased Meflin expression in cancer-associated fibroblasts restrains tumor cell proliferation and shapes vessel-rich stroma in triple-negative breast cancer 1.00
2 1.94
Correlation-Based Morphometric Analysis Reveals Structural Remodeling of Platelet-Bound Circulating Tumor Cells in Urothelial Carcinoma 1.00
Beyond the Nucleus: Cytoplasmic Dominance in Follicular Thyroid Carcinoma Detection Using Single-Cell Raman Imaging across Multiple Devices 0.94
1 1.00
Programmable Antigen-Specific Immunity via Self-Adjuvanting Nanovaccines Co-Delivering Immune Modulators 1.00
11 7.93
Radial Margin Distance in Perihilar Cholangiocarcinoma: Defining Dual Cutoff Values of 0 and 1 mm. 1.00
Surgical Outcomes of Non-Benchmark Perihilar Cholangiocarcinoma: A Multicenter Study from High-Volume Centers in Japan. 1.00
Setting the Standard in Robotic Whipple Surgery: International Multicenter Benchmark Analysis. 0.15
Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. 1.00
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar). 0.03
Robotic Versus Open and Laparoscopic Pancreaticoduodenectomy: A Nationwide Matched Study in Japan. 1.00
Tumor Serosal Invasion in Perihilar Cholangiocarcinoma: A Lethal But Overlooked Feature. 1.00
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. 0.45
International Validation of a Recurrence Risk Model for Stage II Colon Cancer: The SPHERE Study. 0.68
Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled Trial. 1.00
Effect of Double Layer Polyglycolic Acid Felt for Reducing Pancreatic Fistula After Pancreatoduodenectomy: Results of a Multicenter Randomized Control Trial (PLANET-PJ trial). 0.62
5 1.20
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study 0.05
Self-reinforcing IL-1β signaling accelerates the development and recurrence of TCF3::HLF-positive B-ALL 1.00
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability 0.03
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.05
The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NFκB signaling 0.08
5 1.85
Metastatic Lymph Node Burden and Invasive Tumour Features Inform First Recurrence Patterns After Curative-Intent Resection for Intrahepatic Cholangiocarcinoma 0.08
Diagnostic Accuracy of Staging Laparoscopy and Development of a Simple Predictive Score for Peritoneal Disease in Advanced Gastric Cancer 1.00
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.07
Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma 0.45
Genomic and clinical parallels between US and Japanese gastric cancers: a propensity score-matched cohort study 0.25
4 1.33
A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors 1.00
Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1 0.22
Genome-Wide CRISPR Screening Reveals that mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer 0.04
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy 0.06
2 0.01
Plasma signals of lung tumor promotion for molecular cancer prevention 0.00
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction 0.01
1 0.25
Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy 0.25
1 1.00
Fabrication of a self-assembling peptide for the inhibition of cancer cell proliferation by targeting LAT1 1.00
1 0.07
Activation of HIF2 in Cardiac Vasculature Leads to Arterial Remodeling, Dilation, Thrombosis, and Inflammation, Recapitulating Cardiac Involvement in Kawasaki Disease 0.07
1 0.09
ARID1A terminates gastric regeneration to prevent cancer 0.09
1 0.14
Cigarette smoking and long-term incidence of colorectal cancer subclassified by tumor-infiltrating myeloid cells: A prospective cohort study 0.14
2 1.05
Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial 1.00
Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study 0.05
2 0.19
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial 0.14
An Exosome-Based Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer: The ENCODER Multicenter Study 0.04
4 1.40
<atl>iTff2/i marks gastric corpus progenitors that give rise to pyloric metaplasia/SPEM following injury</atl> 0.21
Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study 0.16
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy 0.03
Real-world impact of implementing lumen-apposing metal stents for pancreatic fluid collections: a nationwide Japanese study 1.00
3 2.01
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study. 1.00
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma. 0.96
Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling. 0.05
1 0.11
On-Chip Dynamic Mechanical Characterization: from Cells to Nucleus* 0.11
1 0.01
Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome 0.01
3 1.20
The impact of an organized screening program on gastric cancer incidence: a quasi-experimental study 0.07
Attributable fraction and interaction of tobacco smoking and alcohol drinking on the risk of head and neck cancer: a pooled analysis of 11 prospective cohort studies in Japan 1.00
Maternal prenatal infection and childhood leukaemia: a Childhood Cancer and Leukemia International Consortium (CLIC) meta-analysis 0.13
2 1.38
Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. 0.99
Exosomal Liquid Biopsy for the Early Detection of Gastric Cancer 0.38
14 13.56
The cellular stress sensor HSPB1 regulates the membrane localization of amino acid transporter SLC7A5 in breast cancer 1.00
The tumor suppressor NDRG2 recruits protein phosphatase 2A to suppress STAT5 phosphorylation in adult T-cell leukemia/lymphoma 1.00
A novel synthetic melanin as a potential anticancer agent that induces apoptosis and cyclin D downregulation through distinct pathways 0.82
Targeting EphA2 under DNA damage causes mitotic bypass via p21 induction 1.00
A missense mutation in acyl-CoA synthetase ACSL4 reveals essential residues for catalytic activity in ferroptosis 1.00
Targeting the splicing factor CWC22 induces mitotic slippage through repression of BubR1 expression and CDK1 activity in cancer cells 1.00
CAPN15 is a non-proteasomal, ubiquitin-directed calpain protease that regulates cell adhesion by cleaving E-cadherin 1.00
PKM2 inhibitor suppresses kidney fibrogenesis by disrupting YAP-TEAD-CCN2 transcriptional signaling following ischemia–reperfusion injury 1.00
Chemical and biological characterization of glycidamide-adducted adenine in DNA 1.00
Dissecting stress-activated protein kinase (SAPK)–signaling pathways using multiplex gene knockout HeLa cells 1.00
The receptor tyrosine kinase ErbB2/HER2 governs CDK4 inhibitor sensitivity, timing and irreversibility of the G1/S transition 0.88
The proton-sensing OGR1 receptor and hypoxia-inducible factors promote metal ion-induced inflammatory responses in coronary artery smooth muscle cells 0.86
Loss of angulin-1/LSR promotes vasculogenic mimicry and epithelial-mesenchymal transition in breast cancer 1.00
Molecular basis of the autoregulatory mechanism of motor neuron-related splicing factor 30 1.00
1 1.00
Differences Among Genomic Profiling Tests for Bone and Soft-Tissue Sarcomas in a Universal Health Insurance System. 1.00
1 1.00
Initial evaluation of radioiodine therapy using Imaging for long-term prognosis in thyroid cancer: A retrospective study 1.00
6 1.17
Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC 1.00
Targeting kinesin family member 20A sensitizes stem-like triple-negative breast cancer cells to standard chemotherapy 0.02
IFN-γ–driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy 0.05
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion 0.02
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models 0.02
A distinct mechanism of epigenetic reprogramming silences PAX2 and initiates endometrial carcinogenesis 0.05
19 3.12
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer 0.45
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial 0.07
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort 0.16
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. 0.12
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. 0.09
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study. 0.01
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. 0.18
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. 0.04
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.07
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.09
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 0.06
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial. 0.19
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. 0.07
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. 0.32
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. 0.05
Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis. 0.04
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. 0.04
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial. 1.00
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas 0.07
2 0.13
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma 0.05
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma 0.08
2 2.00
Elaboration of cortical pyramidal dendrites requires dephosphorylation of Signal Regulatory Protein α by Protein Tyrosine Phosphatase δ 1.00
Klf5 Regulates the Transition from Apical Radial Glia to Intermediate Progenitor Cells in the Developing Mammalian Brain 1.00
4 2.09
Three-dimensional CT volumetry and pulmonary function outcomes after segmentectomy versus lobectomy 1.00
Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non–small cell lung cancer 0.02
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer 0.07
Clinical utility of the 5-point visual Deauville score for preoperative evaluation in stage I non–small cell lung cancer: A multicenter retrospective study 1.00
3 2.25
A Cascade-Responsive AND-Logic-Activatable Nanoprobe for Intraoperative Fluorescence Imaging of Colorectal Cancer 0.25
Photoaffinity Labeling Strategy Reveals Tetraspanin CD9 as a Transient Target of Anticancer Yaku’amide B 1.00
Optogenetic Cancer Therapy Using the Light-Driven Outward Proton Pump Rhodopsin Archaerhodopsin-3 (AR3) 1.00
5 0.77
ypTNM versus pTNM staging after neoadjuvant therapy in rectal cancer 0.05
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25) 0.06
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials 0.45
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.18
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.03
3 1.45
BRCA2-dependent maturation of nascent strands during DNA replication 0.25
An interactome-based framework for DDB1- and CUL4-associated factor prioritization in targeted protein degradation 1.00
The E3 ligase RNF32 controls the IκB kinase complex and NF-κB signaling in intestinal stem cells 0.20
5 0.07
Acquired genetic and cell-state changes in IDH-mutant glioma progression 0.00
Evolutionary characterization of lung cancer metastasis 0.00
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma 0.01
Somatic evolution following cancer treatment in normal tissue 0.00
Axonal injury is a targetable driver of glioblastoma progression 0.05
3 1.24
Designing protein-based artificial kinetochores as decoys to prevent meiotic errors in oocytes 1.00
NOX1 and NPY1R mark regional colon stem cell populations that serve as cancer origins in vivo 0.11
Evolutionarily conserved role of telomerase reverse transcriptase in programming the microenvironment via regulation of the cGAS–STING pathway 0.13
1 0.03
Highly specific intracellular ubiquitination of a small molecule 0.03
37 22.50
Inherent tissue homeostasis of the juvenile metaphysis provides a foundation for osteosarcoma development 1.00
Potential for risk reduction of chronic health conditions through lifestyle in childhood cancer survivors 0.06
Allosteric network of dynamic coupling within BAP1-UCH revealed by methyl NMR 0.03
Protein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis 0.97
Immune-induced TCR-like antibodies regulate specific T cell response in mice 1.00
PD-1 antibody-bound progenitor-exhausted CD8+ T cells in lymph nodes boost PD-1-blockade anti-tumor immunity in gastrointestinal cancer 1.00
Ponatinib inhibits LCK and PI3K signaling and promotes CD8+ T stem cell memory cell development 1.00
Bleb-based extravasation uses conserved morphodynamics but divergent calcium control 0.88
Structural basis for prostaglandin and drug transport via SLCO2A1 0.18
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in G12C-mutant advanced solid tumors: a first-in-human study 0.11
Recruitment of BRD4 to the ASXL1 genomic targets depends on the extra-terminal domain of BRD4 0.06
Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer 0.71
14-3-3ζ interacts with DNA-binding domain of FOXO3a and competitively dissociates DNA by dual-motif tethering 1.00
Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC 0.06
A role for condensin-mediator interaction in mitotic chromosome organization 0.54
CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting 0.95
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial 0.02
Ribosome biogenesis as a potential therapeutic target in KRAS mutant colorectal cancer 1.00
Structural dynamics of mixed-subunit CaMKIIα/β heterododecamers filmed by high-speed AFM 1.00
Thrombopoietin increases susceptibility for EVI1 + KMT2A-MLLT3-driven AML expressing stem cell genes linked to poor outcome 0.06
The molecular cartography of malignant and benign sebaceous tumours 0.13
Cancer-associated USP28 missense mutations disrupt 53BP1 interaction and p53 stabilization 1.00
Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study 0.06
EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection 0.05
Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome 1.00
Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial 1.00
Targeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer 0.95
Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities 1.00
Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma 0.05
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy 0.50
Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies 0.14
Structural insights into Wnt/β-catenin signaling regulation by LGR4, R-spondin, and ZNRF3 1.00
Regulatory role of the N-terminal intrinsically disordered region of the DEAD-box RNA helicase DDX3X in selective RNA recognition 1.00
Clonal diversity shapes the tumour microenvironment leading to distinct immunotherapy responses in metastatic urothelial carcinoma 1.00
ALS/FTD-linked TBK1 deficiency in microglia induces an aged-like microglial signature and drives social recognition deficits in mice 0.05
Multi-omics analysis identifies an M-MDSC-like immunosuppressive phenotype in lineage-switched AML with rearrangement 0.95
Functional interplay between condensin I and topoisomerase Iiα in single-molecule DNA compaction 1.00
5 0.19
High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia 0.03
Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases 0.03
Genomic evolution of pancreatic cancer at single-cell resolution 0.03
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.05
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation 0.05
2 1.00
Purine salvage pathway protects CD8 T cells from metabolic stress 0.97
The transcription complex p52–ETS1 is essential for germinal center formation 0.03
11 1.48
Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial 0.72
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial 0.03
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 0.16
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.04
Global and regional cancer burden attributable to modifiable risk factors to inform prevention 0.07
Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade 0.03
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.16
Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results 0.03
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 0.11
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial 0.04
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial 0.08
1 0.11
Brain tumors induce widespread disruption of calvarial bone and alteration of skull marrow immune landscape 0.11
2 1.09
Spatial colocalization and molecular crosstalk of myofibroblastic CAFs and tumor cells shape lymph node metastasis in oral squamous cell carcinoma 0.79
Systematically identification of survival-associated eQTLs in a Japanese kidney cancer cohort 0.30
1 0.11
Long-term outcomes after unilateral salpingo-oophorectomy: A registry-based retrospective cohort study 0.11
11 7.70
MiR-155-driven loss of ICOSL and SOCS1 in EBV+ gastric cancers renders abundant cytotoxic T cells ineffective, enabling immune evasion 0.40
CD28-driven ex vivo generation of stem-like memory CD8+ T cells bypassing CD3/TCR signaling 0.05
Sister chromatid separation determines the proliferative properties upon whole-genome duplication via homologous chromosome arrangement 1.00
Alternative microexon splicing code for a four-amino acid peptide of PTPRD governs behavioral development 1.00
Switching of the c-Myc protein degradation pathway depending on the PP2A-B55α complex levels 1.00
Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis 0.88
Genomic and transcriptomic landscape of carcinogenesis in patients with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) 1.00
Mutant p53 regulates cancer cell invasion in complex three-dimensional environments through mevalonate pathway–dependent Rho/ROCK signaling 0.08
Genetic dissection of nonconventional introns reveals codominant noncanonical splicing code in Euglena 0.97
The activity and expression of adenylosuccinate lyase were reduced during modern human evolution, affecting brain and behavior 0.50
Neutron and time-resolved X-ray crystallography reveal the substrate recognition and catalytic mechanism of human Nudix hydrolase MTH1 0.82
1 0.09
Mesorectal Fascia Involvement by Tumor Deposits or Extramural Vascular Invasion at MRI Predicts Prognosis in Rectal Cancer. 0.09
2 0.88
AQP5: A functional gastric cancer stem cell marker in mouse and human tumors 0.06
Nematode telomerase RNA hitchhikes on introns of germline–up-regulated genes 0.82
6 2.93
Regulation of NAT1 activity in modern humans by a novel phosphorylation site 0.06
Stress-induced CXCL13 regulates pancreatic exocrine homeostasis, age-related chronic inflammation, and cancer progression 0.89
Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation 0.88
Caspase-2 deficiency drives pathogenic liver polyploidy and increases age-associated hepatocellular carcinoma in mice 0.07
Functional landscape of mechanistic diversity in 27 claudin family members at tight junctions 1.00
Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma–GATA3 molecular subgroup 0.03
3 2.00
Clinical validation of an HPV whole-genome sequencing assay for MRD detection in patients with HPV+ head and neck cancer treated with surgery 0.01
On-demand GLUT3 expression augments CAR T cell metabolic fitness and antitumor efficacy in preclinical models of glioblastoma 1.00
Cationic nanogel–based nasal therapeutic HPV vaccine prevents the development of cervical cancer 0.98
6 4.20
Phosphorylation tunes p62 condensates to drive autophagic degradation of ubiquitinated proteins 1.00
Dual pathways via CENP-C and Mis18C recruit HJURP for CENP-A deposition into vertebrate centromeres 1.00
Targeting myoferlin in ER/Golgi vesicle trafficking reprograms pancreatic cancer-associated fibroblasts. 0.07
Nucleosome interaction of the CPC secures centromeric chromatin integrity and chromosome segregation fidelity 0.13
Polyubiquitin architecture editing on collided ribosomes maintains persistent RQC activity. 1.00
MPS1 promotes timely spindle bipolarization to prevent kinetochore-microtubule attachment errors in oocytes. 1.00
8 1.39
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial 0.04
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study 0.03
Progress towards the WHO Global Initiative for Childhood Cancer target of 60% 5-year survival for all childhood cancers combined, 1990–2019 (CONCORD-4): a Cancer Survival Index derived for 68 countries by analysis of individual records for 613 021 children from 307 population-based cancer registries 0.06
Cumulative incidence of advanced breast cancer in women aged 40–49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis 1.00
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study 0.03
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial 0.12
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
1 0.07
Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial 0.07
9 1.98
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial 0.50
Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial 0.09
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.04
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.03
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.08
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study 1.00
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study 0.11
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 0.11
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial 0.02
20 1.23
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma 0.03
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer 0.05
Perioperative Apalutamide in High-Risk Localized Prostate Cancer 0.04
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer 0.05
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer 0.05
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy 0.02
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.03
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.08
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer 0.19
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer 0.04
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer 0.05
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.03
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.02
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 0.09
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 0.10
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.03
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 0.06
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.14
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.07
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.04
1 1.00
Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study 1.00

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.